Drugs / Zika Virus Immune Globulin (ZIKV-IG)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03624946 | Jun 2018 → Mar 2019 | Zika virus infectious disease | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zika Virus Immune Globulin (ZIKV-IG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03624946 ↗ |
| Known as | Anti-Zika Immune Globulin (Human) | “Anti-Zika Immune Globulin (Human)” NCT03624946 ↗ |
| Modality | Protein / enzyme biologic | “human immune globulin preparation containing neutralizing antibodies to Zika virus” NCT03624946 ↗ |
| Route | Intravenous | “administered intravenously over 33 minutes.” NCT03624946 ↗ |